Background. Cytomegalovirus (CMV) infection is implicated in endothelial dysfunction and graft damage after pediatric heart transplantation. CMV-specific immune responses are thought to be necessary for CMV viral control but there is little data in pediatric heart transplantation. Methods. We studied 28 consecutive pediatric heart transplant recipients for 1 year posttransplant. CMV T-cell expressing IFN-γ, TNF-α, and IL-2 in response to ex vivo stimulation with CMV lysates or peptides were measured. Circulating cytokines were measured in plasma. Generalized Additive Models were applied to the data to model changes of cell population dynamics over time. Results. CMV-specific T cell-mediated responses were impaired in the first 8 weeks posttransplant. During this period, 25% of patients had CMV viremia, of which those with VLs of 10000 or more CMV deoxyribonucleic acid copies/mL were given ganciclovir. In this group, the frequency of CD4+ and CD8+ T cells producing IFN-γ and the CD8+CD57+ granzyme B+ T-cell population increased at 12 to 24 weeks and remained elevated for the duration of the study. Conclusions. We have shown that CMV viremia is associated with CMV-specific immune responses and increased CD8 +CD57+ granzyme B+ cells at 1 year posttransplant; however, early responses were not predictive of impending CMV viremia. It remains to be seen if the early CMV immune response detected is associated with endothelial and allograft damage, in light of previous studies demonstrating increased vasculopathy in pediatric patients with CMV viremia.
H uman cytomegalovirus (CMV) is a ubiquitous doublestranded deoxyribonucleic acid (DNA) virus. Although CMV infection is usually asymptomatic in the healthy population, it remains an important cause of morbidity and mortality among immune-compromised patients, including children undergoing cardiac transplants. 1, 2 One peculiarity of CMV is its particular tropism for endothelial and epithelial cells 3 which may explain its postulated role in arterial hypertension and aortic atherosclerosis 4 and other cardiovascular diseases, 5, 6 including cardiac allograft vasculopathy (CAV) in adults. [7] [8] [9] CMV-specific T-cell immune responses can be used to predict CMV tissue invasive diseases and complications in adult transplant recipients. [10] [11] [12] [13] [14] [15] After heart transplantation in adults, an adequate immune response is crucial to control the viral burden and appears to limit vascular damage. 16 We have previously linked CMV infection to pediatric allograft vasculopathy 17 and shown the association of CMV viremia in pediatric cardiac transplant recipients to endothelial dysfunction. 18 However, our studies were not prospective, and we did not assess CMV cell mediated immune responses. Longitudinal immunological studies are difficult in pediatric heart transplantation because of the small populations and the difficulties in blood sampling, exemplified by a recent study highlighting only 3 heart transplant recipients with CMV as part of a wider cohort. 13 Understanding posttransplant immune reconstitution and CMV-specific immune response dynamics may provide insight to the risks of developing CMV related complications, such as cardiac allograft vasculopathy.
In the current prospective study, 28 children were followed up for the first year after heart transplant to explore the dynamics of the CMV-specific T-cell population by evaluating the cellular response to total viral lysate and peptides by measuring intracellular cytokine production, specifically interleukin-2 (IL-2), tissue necrosis factor (TNF)-α, and interferon (IFN)-γ. Reduced levels of IFN-γ have been associated with increased CMV viral load (VL). 19 Furthermore, reduced levels of polyfunctional T cells (those expressing more than 1 cytokine) have been associated with CMV viral replication, 20 and that these polyfunctional T cells protect against the chronic longterm effects of viral infections. Levels of CD8 + CD57
+ T cells were also evaluated. These cells are known to replicate in response to CMV infection and produce Granzyme B (GB), 21, 22 which can trigger apoptosis and graft damage. In addition, we examined soluble biomarkers of inflammation and vascular function. Data was analyzed using a generalized additive mixed model (GAMM) to explore the dynamics of cell populations in different patient groups over time.
MATERIALS AND METHODS

Study Design and Patient Population
Children undergoing heart transplantation at Great Ormond Street Hospital (GOSH) from September 2009 to July 2011 were prospectively enrolled in the longitudinal cohort study. The study was conducted after obtaining the local ethical committee approval and in accordance with guidelines provided by the National Research Ethic Service. The immunosuppressive regimen for these patients was as follows: induction immunosuppression with Basiliximab and highdose intravenous steroids. Maintenance was with tacrolimus and mycophenolate mofetil with oral steroids weaned by 6 months. Target tacrolimus levels were also reduced after 6 months from 9 to 12 to 7 to 10 μg/L. Prophylactic treatment with nystatin, cotrimoxazole, and aciclovir was given for the first 3 months after transplantation.
Patients were screened and monitored for CMVand EpsteinBarr virus DNAemia, and tacrolimus levels, renal and liver function, and full blood count were checked at every clinical visit (weekly for the first month, every 2 weeks for 2 months, then monthly for the rest of the year). CMV DNAemia was detected by CMV polymerase chain reaction at the GOSH diagnostic laboratory according to the method of Preiser.
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The UK pediatric heart transplant units use preemptive treatment for CMV viremia, not prophylactic treatment. Antiviral therapy with ganciclovir was only given when CMV VL was 10000 or greater CMV DNA copies/mL.
The CMV serostatus of donors (D) and recipients (R) was established before transplantation by measuring specific immunoglobulin to CMV by enzyme-linked immunosorbent assay. For patients younger than 18 months, IgM and IgG antibodies were measured, and CMV-positive status given if the patient had IgM and IgG antibodies to CMV. At the time of transplant, patients were defined as being R+D+, R+D−, R−D+ and R−D−. Of the 6 patients that were younger than 18 months, all, except 1 patient, were D+/R−. The 1 patient that was R+/D− was in the CMV+VL− group.
For the purposes of this study, children were divided into 3 groups: (1) patients, exposed to CMV before or at transplant, who had posttransplant viral replication (CMV+VL+); (2) patients exposed to CMV before or at time of transplant, who had no viral replication (CMV+VL−); and (3) patients who had neither previous CMV exposure (CMV−) nor viral replication. Demographics of the patients included in the analysis are shown in Table 1 .
Sample Collection and Processing
Blood samples were collected, when possible, before or on the day of the heart transplant (W0), at weeks 1, 2, and 4, and then 4 weekly, for up to a year. Plasma was separated and stored at −80°C, and peripheral blood mononuclear cells (PBMCs) were isolated from heparinised blood by density gradient centrifugation (lymphoprep; Axis-Shield PoC AS, Oslo, Norway) and processed immediately. CMV-specific responses and ex vivo cell proportions were detected using flow cytometry. Soluble markers were detected using a MSD multiarray assay (Meso Scale Discovery; Rockville, MD). Details of reagents and methods are described in Materials and Methods, SDC, http://links.lww.com/TP/B544.
Cell Stimulation and Staining
Cells (2 Â 10 6 ) were stimulated with 5 μg/mL of either viral peptides (IE-1 and pp65; JPT Peptide Technologies GmbH, Berlin, Germany) or purified viral lysate (Advanced Biotechnologies Inc., Columbia, MD) or SEB (Sigma-Aldrich Company Ltd., Gillingham, UK) as positive control or left unstimulate (negative control) in the presence of 5 μg/mL costimulatory monoclonal antibody, anti-CD28 (BD Biosciences, Oxford, UK). After 2 hours, complete medium containing Brefeldin A (Sigma-Aldrich; final concentration 10 μg/mL) was added and incubated for a further 14 hours.
All antibodies were from BD biosciences except for the anti-human GB antigen, which was from Life Technologies Ltd (Paisley, UK). Cells were first costained with anti-CD3 (Pacific Blue; clone MOPC-21) anti-CD4 (APC-Cy7; clone SK3) and anti-CD8 (PerCP-Cy5.5; clone SK1), fixed with 4% paraformaldehyde (PFA), permeabilized with phosphate buffer saline containing 2% bovine serum albumin and 0.1% saponin, and then stained with anti-IL-2 (FITC; clone 3544.111), anti-TNF-α (PE; clone MAb11) and anti-IFN-γ (APC; clone B27). Peripheral blood mononuclear cells were finally suspended in PFA and stored at 4°C until acquisition on an LSRII flow cytometer (BD biosciences), equipped with 4 lasers (350, 405, 488, and 633 nm). The instrument was calibrated on a weekly basis. At least, 100000 events were collected. 
a Of the 6 patients that were less than 18 months, all except 1 patient were D+/R−. The 1 patient that was D−/R+ was in the CMV+VL− group. There were no infant donors (<2 years of age). There was no significant difference in age between the 3 patient groups (ANOVA).
Acquired data were analyzed using FlowJo v9.6.5 (TreeStar, Celeza GmbH, Olten, Switzerland). Figure S1 , SDC, http://links.lww.com/TP/B544 shows representative plots and gating strategy of a control sample, gated on IFN-γ-expressing cells. CD3+CD4+ and CD3+CD8+ T cells were expressed as percent frequency of the total CD4 or CD8 T-cell population. The CD8+ or CD4+ T lymphocytes were considered to respond to stimulation when cytokines levels were equal to or above an arbitrary threshold, set on the unstimulated control at +0.25%.
1 Â 10 6 PBMCs were stained with anti-CD3 (Pacific Blue), anti-CD4 (APC-Cy7), anti-CD8 (PerCP-Cy5.5) and anti-CD57 (FITC; clone HNK-1; Life Technologies Ltd. Cells were then fixed with 4% PFA and permeabilized as above before adding the anti-GB (APC; clone GB11) antibody. After the staining, the cells were stored at 4°C until flow cytometry acquisition.
Statistical Analysis
Generalized additive mixed models (GAMM) were used to model the temporal pattern of the cell population dynamics. Where the response variable was expressed as 0/1 values (eg, the CD8-IFN-γ response to CMV lysate, pp65 or IE-1 peptide greater or equal to 0.25% above control), a binomial distribution with logit link function was used. The proportion of the CD57+GB+ population was modeled using a beta distribution with logit link function to handle the continuous and bounded (0-1) nature of the data. This model afforded considerably better fit to the observations and model diagnostics to the observations than a quasibinomial. We used GAMMs because we anticipated nonlinear functional responses on the scale of the linear predictor. Generalized additive mixed models allow the estimated nonlinear relationships be determined from the data via the use of local spline basis functions, rather than be specified a priori by an analyst. Modern advances in additive model theory (eg, Wood et al 24 ; Wood 25 ) have demonstrated the applicability and appropriateness of using GAMMs for applied statistical modeling where the true shape of the (partial) relationships between response and covariate is unknown or not representable using simple low-degree polynomials.
All models were fitted using the mgcv package [26] [27] [28] for the R statistical Software (version 3.2. 2 29 ). Details of the GAMMs fitted are available in SDC, Materials and Methods.
RESULTS
Patient Recruitment and Group Demographics
Thirty-four children, aged between 5 months and 16 years were recruited for the study. Six children were excluded from the study. Three did not receive a transplant during the study period, 1 died, and insufficient sample was obtained from 2 to be included in the analysis. Patients were stratified according to their CMV status at transplant and whether or not they had viremia postoperatively. Patient demographics can be viewed in Table 1 . Patients that were either R+ or D+ and had CMV viremia were CMV+VL+ (n = 7; median age, 2.12 ± 6.45 y); patients that were R+ or D+, but did not have CMV viremia, were CMV+VL− (n = 10; median age, 8.84 ± 5.65 y); patients that were D−/R− and had no CMV viremia were in the CMV−VL− group (n = 11; median age, 7.58 ± 6.45 y). In the CMV+VL+ group, 2 patients were D+R+ and 5 D+R−. In the CMV+VL− cohort, 1 patient was D+R+, 3 patients were D+R− and 6 D−R+. All patients in the CMV−VL− group were D−R−.
Posttransplant CMV Viremia
Seven (41%) of the 17 "at risk" patients had CMV DNA detected in the blood within the first 12 weeks posttransplant ( Figure 1 ). Among those children who had viremia, 2 (22%) of 7 of them (Figure 1 ; patient number 1 and 2) were R+/D+ and had detectable CMV reactivation/reinfection (median, 1045 copies/mL; range, 0-2715 copies/mL) at weeks 9 to 11. However, the VL was below the threshold at which anti-CMV treatment is administered, and these patients were able to control viral replication without medication. In the remaining 5 (78%) of the 7 viremic children (all R−/D+), CMV DNA was detected within the first 7 weeks after transplantation, with a maximal median CMV VL of 20924 copies/mL (range, 0-182316 copies/mL) at weeks 6 to 9. These patients required treatment with ganciclovir.
Dynamics of CMV-specific T-cell Responses After Peptides and Viral Lysate Stimulation
To assess CMV-specific T-cell response in the 3 cohorts, we measured the percentage of CD4+ and CD8+ T cell populations producing intracellular IFN-γ, TNF-α, and IL-2 ( Figure S1 , SDC, http://links.lww.com/TP/B544) after stimulation with whole CMV lysate, IE-1 and pp65 peptides. T-cell responses to a nonantigenic stimulus were evaluated using bacterial superantigen SEB ( Figure S2A and B, SDC, http://links.lww.com/TP/B544), and there was no statistically significant difference in response to SEB in CD4+ and CD8+ cells between the different patient groups.
In patients from the CMV+VL+ cohort, CD8+ and CD4+ T lymphocytes producing IFN-γ in response to 1 or more CMV stimuli were below the positive response threshold (>0.25% positive) for 8 and 12 weeks, respectively (Figure 2A ). After 20 to 24 weeks, the frequency of IFN-γ-producing T lymphocytes increased above the positive response threshold, peaking at 28 weeks (1.96% median CD4+IFN-γ+ cells; 3.53% median CD8+IFN-γ+ cells). Both CD4+ and CD8+ cells retained the capacity to produce IFN-γ above the response threshold until the end of the 52-week period. The frequency of TNF-α-producing CD4+ and CD8+ T cells was low throughout the study period (data not shown). Lymphocytes from the CMV+VL+ cohort did not show any augmentation in IL-2 synthesis in response to stimulation (data not shown).
In the CMV+VL− cohort, the frequency of detectable IFN-γ-producing cells fluctuated around the response threshold. IFN-γ produced by CD8 cells was above the response threshold at 16 weeks (median, 0.29%), and by week 52, both CD4 and CD8 T cells were producing detectable levels of IFN-γ (median, 0.44% and 0.35%, respectively [ Figure 2B] ). As in the CMV+VL+ group, there was no significant increase in CD4+ or CD8+ cells producing TNF-α or IL-2 in the CMV+VL− patient group (data not shown).
Lymphocytes from patients in the CMV−VL− cohort failed to produce IFN-γ from either CD4+ or CD8+ cells in response to any CMV stimulus ( Figure 2C ). TNF-α and IL-2 were rarely detected and always at low levels (data not shown).
Further investigation of any effects of CMV status and VL on the production of IFN-γ by CD8+ T cells was conducted using the fitted GAMMs (Figure 3 ).
These models (Figure 3 ) demonstrated that in the CMV+VL+ cohort, levels of IFN-γ production by both CD4+ and CD8+ T cells increased significantly after 20 weeks (ie, after the reduction of CMV viremia to undetectable levels), and this increase continued for the duration of the study (χ 2 = 18.07, degrees of freedom (df ) = 9, P < 0.001 for CD4+ cells; χ 2 = 24.13, df = 9, P < 0.001 for CD8+ cells respectively), whereas levels in the CMV+VL− group increased after 30 to 40 weeks posttransplant (P < 0.001 for both CD4+ and CD8+ cells; Figure 3A and B). The model with patientspecific time curves provided a significantly better fit to the data than the common time curve model (likelihood ratio test: χ 2 = 10.39, df = 1.96, P = 0.00528 for CD4-expressing cells and χ 2 = 33.51, df = 5.85, P < 0.001 for CD8-expressing cells).
GB Expression in CD57+ T Cells
The patterns of CD57+ cells expressing GB were distinct for the 3 patient groups (Figure 2 ). In the CMV+VL+ patients, there was a decrease in levels of this population at 4 to 8 weeks, followed by a dramatic increase at week 12. Levels plateaued at 20 weeks, remaining elevated for the rest of the study (Figure 2A ). In contrast, in the CMV+VL− group, these cells remained stable, only increasing at the end of the study period, yet never reaching the levels observed in the CMV+VL+ cohort ( Figure 2B ). Patients in the CMV−VL− group had low percentages of CD8+CD57+GB+ cells after transplant, rising at 12 weeks to levels that were maintained for the remainder of the study period ( Figure 2C ). Frequencies of these cells were always lower in the CMV−VL− group compared to levels in the other 2 groups.
The GAMM showed that in the CMV+VL+ patient cohort, there was an increase in CD57+GB+ CD8 cells around 8 weeks posttransplant, reaching a plateau after 30 weeks, suggesting that the increase in CD57+GB+ cells is after the peak in CMV VL (Figures 2A and 3C ). This increase in CD57+GB+ cell proportion in the CMV+VL+ patient cohort ( Figure 2B and 3C) is significant (χ 2 = 367.97, df = 9, P < 0.001). On the contrary, the CMV+VL− group has a shallower increase in CD57+GB+ cell proportion and appears to reach a lower plateau after 40 weeks (χ 2 = 88.21, df = 9, P < 0.001). Furthermore, there was a significant difference between the time curves of the 2 groups (likelihood ratio test: χ 2 = 36.42, df = 2.13, P < 0.001).
Soluble Markers in Plasma of Heart Transplanted Children Exposed to CMV
There was no convincing evidence that the patterns of soluble markers differed between the 3 groups. The levels of cytokines were low in all groups throughout the year of follow-up (Table S1 , SDC, http://links.lww.com/TP/B544).
Long-Term Patient Outcomes
In the years after this study, we have had 5 deaths in our patient population. Four deaths were due to antibody mediated rejection, of which 2 of those patients were in the CMV−VL− group, 1 was in the CMV+VL− group, and the last patient was in the CMV+VL+ group. This last patient was D+/R+ and the only patient that developed CAV. The fifth patient died due to unrelated circumstances. With our small patient sample size and only 1 patient with CAV, it will be difficult to assess the implication of the immunological markers on the development of CAV. Larger, multicenter studies will be required to truly discern the impact of CMV in a pediatric population unaffected by other confounding factors involved in adult CAV disease post-heart transplant.
CONCLUSIONS
This is the first prospective study of CMV-specific cellmediated immunity in pediatric heart transplantation. During the first 8 weeks after transplantation, CMV-specific responses were rarely detectable. This reflects the impact of the early immunosuppression, which not only influenced CMV-specific responses but also suppressed CD4+ and CD8+ IFN-γ expression in response to SEB stimulation. This period of immunosuppression coincided with detectable CMV VL. CMV became undetectable just before emergence of specific CMV responses in both ganciclovir treated (5) and untreated (2) patient. The detection of CD4+ and CD8+ IFN-γ expression was significantly earlier in patients who had detectable CMV and coincided with reduction of CMV viremia to undetectable levels.
In both CMV+ cohorts, CD8+ and CD4+ cells producing either TNF-α or IL-2 were rarely detected and the plasma levels of these cytokines did not show any appreciable difference when compared to those of the CMV−VL− patients. These finding may at least be partially explained by a decreased capacity to produce CMV-specific IL-2 responses during primary infection 30 and by the ability of CMV to render the CD4+ cells unresponsive to immunological stimuli. 31, 32 It may also reflect the impact of immunosuppression on the cytokine response.
In the United Kingdom, all pediatric heart transplant patients have preemptive therapy for CMV infection. Although reducing exposure to antiviral drugs effect, 33 some patients will develop significant CMV viremia and this strategy can be logistically demanding. Universal prophylaxis reduces early CMV disease but exposes children to medication with potentially harmful side effects. 34 Furthermore, recent work has shown no difference in patient outcome when comparing preemptive therapy and prophylaxis; however, preemptive therapy does reduce the burden of drug exposure in children with liver transplantation. 35, 36 Biomarkers that predict which patients require prophylaxis would be an attractive means of allocating antiviral therapy.
In our study, we did not find that CMV-specific CD4 and CD8 responses were predictive of developing CMV viremia in CMV-positive patients, largely because levels were below the positive threshold before CMV viremia. This indicates that other components of the immune system may be more important in controlling CMV replication and/or that the methods used for detecting CMV-specific immune responses were too insensitive to detect patients at risk of viremia. Interestingly, the high detection levels of early CMV-specific T-cell immune recovery by ELISpot in adult heart transplant recipients provides long-lasting protection to CMV disease, 19 and this technique may be more sensitive for low level detection.
Adult allograft recipients have been shown to have increased numbers of CD8+CD57+ circulating lymphocytes, 30 correlating with CMV carrier status. 31 Although all 3 groups showed an increase in CD8+CD57+GB+ cells after transplant, there was a substantially greater increase in these cells in the CMV+VL+ group at around 8 weeks posttransplant, reaching a plateau after 30 weeks, that is, after the peak in CMV VL. This was significantly earlier than in patients in whom VL was not detectable.
The significance of the increase in CD57+ cells is unclear. We found a strong association between CD57 positivity and GB expression. This population of cells has the potential to cause tissue injury, 37 through the release of potent cytolytic enzymes. Granzyme B production has been linked to allograft rejection in renal transplantation, 38 with inhibition of the cytolytic activity of GB leading to improved transplant survival. We and others have shown that CMV infection is related to cardiac allograft vasculopathy and posttransplant endothelial dysfunction. 17, 18 We hypothesize that the high levels of CD57+ cells in patients with CMV may be involved in the vasculopathy observed in patients with CMV viremia posttransplant, in light of previous work from our group, where we associate CMV viremia with vasculopathy in a similar pediatric population of patients. 18 In conclusion, we have shown that in the first year postpediatric heart transplant, patients with active CMV viral replication display both increased CMV-specific immune responses and an increase in CD8+CD57+GB+ cells. Although these responses were not predictive of impending CMV viremia, they may be involved in endothelial injury. Further studies are required to understand if these cells are responsible for CMV associated posttransplant vasculopathy, and if the virus and/or the potentially damaging immune responses should be targeted to reduce long-term mortality and morbidity.
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